Evidence map›Paper›PMID 25024345›Full record

ArticleJournal of Alzheimer's disease : JAD2014

Validation of a serum screen for Alzheimer's disease across assay platforms, species, and tissues.

Sid E O'Bryant, Guanghua Xiao, Fan Zhang, Melissa Edwards, Dwight C German, Xiangling Yin, Tori Como, Joan Reisch, Ryan M Huebinger, Neill Graff-Radford and 5 more

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Blood-based biomarkers for Alzheimer's disease in Down syndrome: A systematic review and meta-analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Alzheimer's disease plasma biomarkers and physical functioning in a diverse sample of adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. A Blood Screening Test for Dementia with Lewy Bodies for Primary Care.Journal of Alzheimer's disease & Parkinsonism · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sid E O'BryantDepartment of Internal Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA Institute for Aging & Alzheimer's Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA.
Guanghua XiaoDepartment of Clinical Science, UT Southwestern Medical School, Dallas, TX, USA.
Fan ZhangDepartment of Academic and Institutional Resources and Technology, University of North Texas Health Science Center, Fort Worth, TX, USA.
Melissa EdwardsDepartment of Psychology, University of North Texas, Denton, TX, USA.
Dwight C GermanDepartment of Psychiatry, UT Southwestern Medical School, Dallas, TX, USA.
Xiangling YinGarrison Institute on Aging, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Tori ComoDepartment of Internal Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA Institute for Aging & Alzheimer's Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA.
Joan ReischDepartment of Clinical Science, UT Southwestern Medical School, Dallas, TX, USA.
Ryan M HuebingerDepartment of Surgery, UT Southwestern Medical School, Dallas, TX, USA.
Neill Graff-RadfordDepartment of Neurology, Mayo Clinic Jacksonville, Jacksonville, FL, USA.
Dennis DicksonDepartment of Neuro-Oncology, Mayo Clinic Jacksonville, Jacksonville, FL, USA Laboratory Medicine and Pathology, Mayo Clinic Jacksonville, Jacksonville, FL, USA.
Robert BarberInstitute for Aging & Alzheimer's Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA.
James HallInstitute for Aging & Alzheimer's Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA Department of Psychiatry, University of North Texas Health Science Center, Fort Worth, TX, USA.
Padraig O'SuilleabhainDepartment of Neurology and Neurotherapeutics, UT Southwestern Medical School, Dallas, TX, USA.
Paula GrammasGarrison Institute on Aging, Texas Tech University Health Sciences Center, Lubbock, TX, USA.

Funding

ROLE OF GLUTAMATE IN ALZHEIMER'S DISEASEP30AG012300 · NIA · UT SOUTHWESTERN MEDICAL CENTER · PI ROSENBERG, ROGER NEWMAN · 1994 to 2016
$26.6M
Vascular inflammation and neurotoxicity in aging brainR01AG028367 · NIA · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI GRAMMAS, PAULA · 2006 to 2009
$1.3M
Is There a Link Between Alzheimer's and AtherosclerosisR01AG020569 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI GRAMMAS, PAULA · 2004 to 2007
$1.3M
A Blood-Based Screening Tool for Alzheimer's DiseaseR01AG039389 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI O'BRYANT, SID E · 2012 to 2013
$608k
NIA NIH HHS AG020569NIA NIH HHS P30 AG012300NIA NIH HHS P30AG12300NIA NIH HHS R01 AG020569NIA NIH HHS R01 AG028367NIA NIH HHS R01 AG039389NIA NIH HHS R01AG039389
6 · The paper itself

Abstract

backgroundThere is a significant need for rapid and cost-effective biomarkers of Alzheimer's disease (AD) for advancement of clinical practice and therapeutic trials.

objectiveThe aim of the current study was to cross-validate our previously published serum-based algorithm on an independent assay platform as well as validate across tissues and species. Preliminary analyses were conducted to examine the utility in distinguishing AD from non-AD neurological disease (Parkinson's disease, PD).

methodsSerum proteins from our previously published algorithm were quantified from 150 AD cases and 150 controls on the Meso Scale Discovery (MSD) platform. Serum samples were analyzed from 49 PD cases and compared to a random sample of 51 AD cases and 62 controls. Support vector machines (SVM) were used to discriminate PD versus AD versus controls. Human and AD mouse model microvessel images were quantified with HAMAMATSU imaging software. Mouse serum biomarkers were assayed via MSD.

resultsAnalysis of 21 serum proteins from 150 AD cases and 150 controls yielded an algorithm with sensitivity and specificity of 0.90 for correctly classifying AD. This multi-marker approach was then validated across species and tissue. Assay of the top proteins in human and AD mouse model brain microvessels correctly classified 90-100% of the samples. SVM analyses were highly accurate at distinguishing PD versus AD versus controls.

conclusionsThis serum-based biomarker panel should be tested in a community-based setting to determine its utility as a first-line screen for AD and non-AD neurological diseases for primary care providers.

Indexed as

AgedAged, 80 and overAlgorithmsAlzheimer DiseaseAnimalsBiomarkersBrainDiagnosis, DifferentialDisease Models, AnimalFemaleFluorescent Antibody TechniqueHumansImage Processing, Computer-AssistedMaleMice, TransgenicMicrovesselsBiomarkersAlzheimer's diseaseblood-based biomarkersserumspeciestissue

Identifiers

PMID25024345
PMCPMC4400808

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.